

# Newport Beach and Birch Street

---

## Clinical Research Treatment Trial Flowchart

## AML NEWLY DIAGNOSED: NON-INTENSIVE

### UCI 21-216

Gilteritinib+Venetoclax+Azacitidine in patients w/ FLT3 mutant AML not eligible for intensive induction chemotherapy

FLT3 mutation

Mechanism: FLT3 inhibitor

PI: Jeyakumar

Coord: S. Osorio

Accrual: 1/5

## POLYCYTHEMIA VERA

### UCI 21-204

ISIS702843 in patients w/ PD-PC

Mechanism: Antisense oligonucleotide specific for human transmembrane protease serine 6

PI: Fleischman

Coord: K. McAbee

Accrual: 1/5

## CLL RELAPSED/REFRACTORY: 2L+

### UCI 21-209

LOXO-305 + Venetoclax and Rituximab vs. Venetoclax and Rituximab in previously treated CLL/SLL

Mechanism: BTK inhibitor + BCL2 inhibitor + CD20 marker

PI: Coombs

Coord: S. Osorio

Accrual: 1/3

## CLL NEWLY DIAGNOSED: HIGH RISK

### S1925

Venetoclax+Obnutumab early intervention vs. delayed therapy in asymptomatic high-risk CLL/SLL

Mechanism: BCL2 inhibitor +anti-CD20 monoclonal antibody

PI: Coombs

Coord: S. Osorio

Accrual: 1/10

### CRC: ADJUVANT

#### NRG-GI005/COBRA

(SOC vs mFOLFOX6 or CAPOX or surveillance)

PI: Zell  
Coord: L. Aguilar  
Accrual: 2/5

### GASTRIC/GEJ: NEWLY DIAGNOSED METASTATIC

#### EA2183

(SOC + XRT)

PI: Seyedin  
Coord: J. Koff  
Pending activation

#### UCI 21-193

(FGFR inhibitor + mFOLFOX6 +  
antiPD-L1 (nivolumab))

PI: Dayyani  
Coord: M. Nguyen  
Accrual: 1/12

### CRC: 1L METASTATIC

#### UCI 21-110

(only EC naïve patients with BRAFV600E CRC)  
Encorafenib + cetuximab + ERAS-007

PI: Dayyani  
Coord: P. Yang  
Accrual: 6/15

### GASTRIC/GEJ: NEOADJUVANT

#### UCI 21-191

(SOC therapy with ctDNA testing)

PI: Dayyani  
Coord: A. Luna  
Pending activation

## NON-TREATMENT/BASIC SCIENCE

UCI 18-136

PI: Parajuli  
Coord: B. Sanchez/C. Carlton  
Accrual: 59/100

UCI 17-05 (BRCA1 -/+)

PI: Parajuli  
Coord: B. Sanchez  
Accrual: 48/75

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

## ADJUVANT

A011801 (HER2+)

Antibody drug conjugate + kinase inhibitor

PI: Parajuli  
Coord: Stephany Ruiz  
Accrual: 2/5

UCI 22-141 (TNBC)

PDL-1 inhibitor

PI: Parajuli  
Coord: Stephany Ruiz  
Accrual: 0/5

## 1L METASTATIC

## 2L METASTATIC

## 3L METASTATIC

**ETCTN 10546 (TNBC)**Cytidine deaminase (CDA) inhibitor + nucleoside hypomethylating agent (HMA)

PI: Parajuli; Coord: K. Kaminski/D. Huttar

Accrual: 1/5

**UCI 19-145 (HR+/HER2-)**CDK 4/6 inhibitor + ER Regulator + Aromatase Inhibitor

PI: Mehta; Coord: S. Ruiz

Accrual: 8/20

**UCI 21-212 (TNBC)**Antibody drug conjugate

PI: Parajuli; Coord: St. Ruiz/J. Miranda

Accrual: 0/3

**ETCTN 10551 (germline BRCA 1/2+)**Hu5F9-G4 (magrolimab) recombinant humanized anti-CD47 mAb IgG4

PI: Parajuli; Coord: J. Miranda

Accrual: 0/5

**UCI 22-139 (HR+/HER2-)**PI3K/mTOR inhibitor

PI: Parajuli; Coord: Alexis Chavez

Accrual: 2/5

**UCI 22-114 (ER+/HER2-)**Proteasome-mediated degradation

PI: Parajuli; Coord: Alexis Chavez

Accrual: 3/5

## HCC: LOCOREGIONAL

### UCI 19-49

Cabo + Ipi/Nivo + TACE

PI: Dayyani  
Coord: Han Nguyen  
Accrual: 15/35

## HCC: 1-3L

### UCI 22-106

STAT3 ± Pembrolizumab or ± Atezolizumab and Bevacizumab

PI: Dayyani  
Coord: H. Nguyen  
Accrual: 3/10

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

## PANCREATIC: BORDERLINE/LOCALLY ADVANCED

### ETCTN-10366

M3814 (Peposertib) + radiation therapy

PI: Dayyani  
Coord: H. Nguyen  
Accrual: 4/8

## MELANOMA: NON-TREATMENT

### UCI 19-135

DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)

PI: Yamamoto  
Coord: A. Reipolska  
Accrual: 64/70

## SARCOMA: RECURRENT

### ETCTN 10556

Ipilimumab and Nivolumab +/- Cabozantinib

PI: Chow  
Coord: B. Huynh  
Accrual: 0/5

## KRAS

UCI 22-75KRAS targeted Vaccine

PI: Valerin  
 Coord: M. Duron  
 Accrual: 0/7

## ALL-COMERS

UCI 22-213E7386 + Pembro +/- Lenvatinib

PI: Dayyani  
 Coord: N. Arechiga  
 Accrual: 0/7

## CLDN18.2

UCI 21-10Bispecific antibody (anti-CLDN18.2 + anti-4-1BB)

PI: Dayyani  
 Coord: K. Ghio  
 Accrual: 8/10

## NON-TREATMENT

UCI 20-101

(Biospecimen Collection for patients planned to start treatment)

PI: Senthil  
 Coord: N. Arechiga  
 Accrual: 53/80

SWOG S1823Low risk group (Stage I/IA)Moderate risk group (Stage IIA/IB)High risk group (nonseminoma Stage IS only)

PI: Rezazadeh  
 Coord: K. Cung  
 Accrual 3/8